George M. Rodgers, III
( out of 101 reviews )

George M. Rodgers, III, MD, PhD

Languages spoken: English

Clinical Locations

Primary Location

St. George Specialty Clinic at Richens Eye Center

Hemophilia Outreach Clinic
161 W 200 N
St. George , UT 84770
801-213-8301
Get Directions

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106
801-581-2000
Get Directions

  • George M. Rodgers, M.D., Ph.D. is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. He started at the University of Utah in 1988. He is the senior adult hemophilia and thrombosis expert in the state of Utah, and also serves as a classical hematology expert for - and receives referrals and consultations from - a six state region. His clinical practice is conducted at the University of Utah's Sugarhouse Clinic. He is the chairman of the University Hospital Adverse Drug Reaction Subcommittee. He is also a principal investigator for clinical trials and the Associate Director of the Utah Center for Bleeding and Clotting Disorders.


    For questions regarding Dr. Rodgers' practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Hematology)
    National Board of Medical Examiners
    Federal Licensing Examination
    American Board of Pathology (Sub: Hematology)
    American Board of Internal Medicine (Internal Medicine)

    Patient Rating

    4.9 /5
    ( out of 101 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    SUGAR HOUSE HEALTH CENTER

    Dr Rodgers was incredible. He listened and ordered appropriate test. I'm so pleased my care is in his hands. Thank you

    SUGAR HOUSE HEALTH CENTER

    kind and caring -- knowledge -- one of your very best

    SUGAR HOUSE HEALTH CENTER

    Spent approximately 20 minutes with him. I spent more than 35 minutes with the student doctor, she asked a lot of questions. She listened intently to my responses. He isn't a good listener. Didn't feel he cared one way or another.

    SUGAR HOUSE HEALTH CENTER

    Dr Rodgers and his staff have given me exceptional care. I'm so appreciative how they listened to all of my concerns and help me with everything, including how to help with lowering the cost of my expensive medication.

    Sugar House Health Center

    All good

    SUGAR HOUSE HEALTH CENTER

    Dr. Rogers was so kind and listened and answered all of my questions

    SUGAR HOUSE HEALTH CENTER

    The best

    SUGAR HOUSE HEALTH CENTER

    Provider looked and talked to wife rather than patient. I wanted my husband to feel involved.

    SUGAR HOUSE HEALTH CENTER

    Dr acted angry when I told him I hadn't gotten the COVID vaccine. It seems he's forgotten or doesn't care that I have multiple health issues I deal with on a daily basis.

  • George M. Rodgers, M.D., Ph.D. is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. He started at the University of Utah in 1988. He is the senior adult hemophilia and thrombosis expert in the state of Utah, and also serves as a classical hematology expert for - and receives referrals and consultations from - a six state region. His clinical practice is conducted at the University of Utah's Sugarhouse Clinic. He is the chairman of the University Hospital Adverse Drug Reaction Subcommittee. He is also a principal investigator for clinical trials and the Associate Director of the Utah Center for Bleeding and Clotting Disorders.


    For questions regarding Dr. Rodgers' practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Sub: Hematology)
    National Board of Medical Examiners
    Federal Licensing Examination
    American Board of Pathology (Sub: Hematology)
    American Board of Internal Medicine (Internal Medicine)

    Education history

    Undergraduate Biochemistry - Louisiana State University B.S.
    Doctoral Training Pharmacology - Tulane University Ph.D.
    Professional Medical Medicine - Tulane University M.D.
    Internship Baylor College of Medicine Intern
    Residency Internal Medicine - Baylor College of Medicine Resident
    Fellowship Hematology/Oncology - University of California San Francisco Fellow

    Selected Publications

    Journal Article

    1. George WJ, Rodgers GM, White L (1978). Cyclic nucleotides as regulators of erythrocyte proliferation. Advances in cyclic nucleotide research, 9, 517-32. (Read full publication)
    2. Heikal NM, Murphy KK, Crist RA, Wilson AR, Rodgers GM, Smock K (2013). Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events. American journal of clinical pathology, 140(5), 680-5. (Read full publication)
    3. Gilreath JA, Stenehjem DD, Rodgers G (2014). Diagnosis and treatment of cancer-related anemia. American journal of hematology, 89(2), 203-12. (Read full publication)
    4. Smock KJ, Rodgers G (2010). Laboratory evaluation of aspirin responsiveness. American journal of hematology, 85(5), 358-60. (Read full publication)
    5. Smock KJ, Rodgers G (2009). Laboratory identification of lupus anticoagulants. American journal of hematology, 84(7), 440-2. (Read full publication)
    6. Rodgers GM, Barrera E Jr, Martin R (1980). Bacillus cereus bacteremia and hemolytic anemia in a patient with hemoglobin SC disease. Archives of internal medicine, 140(8), 1103-4. (Read full publication)
    7. Smock KJ, Crist RA, Hansen SJ, Rodgers GM, Lehman C (2010). Discard tubes are not necessary when drawing samples for specialized coagulation testing. Blood coagulation & fibrinolysis, 21(3), 279-82. (Read full publication)
    8. Lim MY, Wei G, Presson AP, Bray P, Rodgers G (2020). High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature. Blood coagulation & fibrinolysis, 31(8), 522-529. (Read full publication)
    9. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin M (1992). [Pre-eclampsia: a disorders of the endothelial cells?]. Der Gynakologe, 25(1), 2-6. (Read full publication)
    10. Lee M, Rodansky ES, Smith JK, Rodgers G (2012). ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis. Microvascular research, 84(2), 109-15. (Read full publication)
    11. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton R (2010). Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thrombosis research, 125(3), 220-3. (Read full publication)
    12. Shirts BH, Rodgers GM, Smock K (2012). Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer. Thrombosis research, 130(3), e134-8. (Read full publication)
    13. Bentley MJ, Lehman CM, Blaylock RC, Wilson AR, Rodgers G (2010). The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion, 50(8), 1654-64. (Read full publication)
    14. Lee M, Keener J, Xiao J, Long Zheng X, Rodgers G (2015). ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. Cellular and molecular life sciences, 72(2), 349-56. (Read full publication)
    15. Williams LB, Javed A, Sabri A, Morgan DJ, Huff CD, Grigg JR, Heng XT, Khng AJ, Hollink IHIM, Morrison MA, Owen LA, Anderson K, Kinard K, Greenlees R, Novacic D, Nida Sen H, Zein WM, Rodgers GM, Vitale AT, Haider NB, Hillmer AM, Ng PC, Shankaracharya, Cheng A, Zheng L, Gillies MC, van Slegtenhorst M, van Hagen PM, Missotten TOAR, Farley GL, Polo M, Malatack J, Curtin J, Martin F, Arbuckle S, Alexander SI, Chircop M, Davila S, Digre KB, Jamieson RV, DeAngelis M (2019). ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. Genetics in medicine, 21(9), 2103-2115. (Read full publication)
    16. Sangle NA, Rodgers GM, Smock K (2011). Prevalence of heparin in samples submitted for lupus anticoagulant testing. Laboratory hematology, 17(1), 6-11. (Read full publication)
    17. Crist RA, Gibbs K, Rodgers GM, Smock K (2009). Effects of EDTA on routine and specialized coagulation testing and an easy method to distinguish EDTA-treated from citrated plasma samples. Laboratory hematology, 15(4), 45-8. (Read full publication)
    18. Lip GY, Halperin JL, Petersen P, Rodgers GM, Pall D, Renfurm R (2015). A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2). Journal of thrombosis and haemostasis, 13(8), 1405-13. (Read full publication)
    19. Aapro M, Gascón P, Patel K, Rodgers GM, Fung S, Arantes LH Jr, Wish (2019). Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. Frontiers in pharmacology, 9, 1498. (Read full publication)
    20. Rodgers GM, Ward JH, Bray P (2022). 80¿years of Clinical Hematology. British journal of haematology, 198(5), 802. (Read full publication)
    21. Auerbach M, Macdougall IC, Rodgers GM, Deloughery T, Richards (2022). The iron revolution: Keeping abreast of the developments in iron therapy. American journal of hematology, 97(3), 250-252. (Read full publication)
    22. Abou-Ismail MY, Rodgers GM, Bray PF, Lim M (2021). Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management. Research and practice in thrombosis and haemostasis, 5(2), 356-365. (Read full publication)
    23. Roberts JC, von Drygalski A, Zhou JY, Rodgers GM, Ansteatt K, Tarantino M (2022). Five Challenging Cases of Hereditary Antithrombin Deficiency Characterized by Thrombosis or Complicated Pregnancy. Journal of blood medicine, 13, 611-618. (Read full publication)
    24. Rodgers GM, Mahajerin (2023). Antithrombin Therapy: Current State and Future Outlook. Clinical and applied thrombosis/hemostasis, 29, 10760296231205279. (Read full publication)
    25. Lim MY, Rodgers GM, Branch DW, Simonsen S (2024). Targeting a higher plasma VWF level at time of delivery in pregnant individuals with von Willebrand disease: Outcomes at a single-institution cohort study. Haemophilia, 30(2), 470-477. (Read full publication)
    26. Sholzberg M, Khair K, Yaish H, Rodgers G, Cruz MS, Mejía CM, ¿ermáková Z, Matino D, Teitel J, Barrie A, Werner S, Prondzinski MV (2021). Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease. TH open, 5(3), e264-e272. (Read full publication)
    27. Martin C, Varner MW, Branch DW, Rodgers G, Mitchell M (1996). Dose-related effects of low dose aspirin on hemostasis parameters and prostacyclin/thromboxane ratios in late pregnancy. Prostaglandins, 51(5), 321-30. (Read full publication)
    28. Lim MY, Sivaloganathan V, Rodgers GM, Simonsen S (2025). Development and validation of an algorithm to better identify pregnant women with inherited bleeding disorders within electronic health records. Thrombosis research, 246, 109253. (Read full publication)

    Review

    1. Rodgers G (2024). Update on iron supplementation in patients with cancer-related anemia. Expert review of hematology, 17(8), 505-514. (Read full publication)

    Book

    1. Bennett ST, Lehman CM, Rodgers G (2014). Laboratory Hemostasis: A Practical Guide For Pathologists.

    Edited Book

    1. Greer JP, Arber DA, Glader BE, List A, Means RT, Paraskevas F, Rodgers G (2014). Wintrobe's Clinical Hematology - 13th Edition.

    Book Chapter

    1. Shami PJ, Rodgers G (2014). Chapter 19, Endothelium: angiogenesis and the regulation of hemostasis. 498¿507.
    2. Rodgers GM, Lehman C (2014). Chapter 45, Diagnostic approach to the bleeding disorders. 1043-1057.
    3. Rodgers G (2014). Chapter 46, Thrombocytopenia: pathophysiology and classification. 1058-1060.
    4. Agarwal AM, Rodgers G (2014). Chapter 49, Miscellaneous causes of thrombocytopenia. 1097-1105.
    5. Rodgers GM, Rees M (2014). Chapter 50, Bleeding disorders caused by vascular abnormalities. 1106-1121.
    6. Powell JS, Rodgers G (2014). Chapter 53, Inherited coagulation disorders. 1143-1185.
    7. Rodgers G (2014). Chapter 54, Acquired coagulation disorders. 1186-1217.
    8. Pendleton RC, Rodgers G (2014). Chapter 55, Thrombosis and antithrombotic therapy. 1218-1257.
    9. Rodgers GM, Means R (2014). Chapter 51, Thrombocytosis and essential thrombocythemia. 1122-1127.

    Editorial

    1. Crawford J, Rodgers G (2014). Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?. Journal of the National Comprehensive Cancer Network, 12(5 Suppl), 821-4. (Read full publication)
    2. Gilreath JA, Rodgers G (2014). Current quandaries in cancer-associated anemia. Journal of the National Comprehensive Cancer Network, 12(8), 1071-5. (Read full publication)
    3. Rodgers GM, Gilreath J (2025). Will Prolyl Hydroxylase Inhibitors Supplant Erythropoiesis-Stimulating Agents and IV Iron in the Treatment of Chemotherapy-Induced Anemia?. Journal of clinical oncology, 43(2), 118-121. (Read full publication)

    Letter

    1. Win K, Rodgers G (2014). New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. American journal of hematology, 89(10), 1017. (Read full publication)
    2. Rodgers, George (2014). Age-Specific differences in the Levels of Hemostatic Proteins: A Rebuttal. Thrombosis and haemostasis, 12, 258.
    3. Patel SB, Rodgers G (2014). Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease. Haemophilia, 20(6), e411-4. (Read full publication)
    4. Rodgers G (2014). Developmental hemostasis: age-specific differences in the levels of hemostatic proteins: a rebuttal. Journal of thrombosis and haemostasis, 12(2), 285. (Read full publication)
    5. Auerbach M, Adamson J, Bircher A, Breymann C, Fishbane S, Gafter-Gvili A, Gasche C, Gilreath J, Grazzini G, Henry D, Liumbruno G, Locatelli F, Macdougall I, Munoz M, Rampton D, Rodgers G, Shander (2015). On the safety of intravenous iron, evidence trumps conjecture. Haematologica, 100(5), e214-5. (Read full publication)

    Abstract

    1. *Lee M, Hoyt C, Rodgers G (2013). ADAMTS13 expressed in glioblastoma and astrocytoma cells can modulate endothelial cell migration. Blood, 122(21), #2306.
    2. *Desai DS, Lyon E, Rodgers GM, Jama AJ, Wallentine SL, Smock K (2013). Gene sequencing aids in differentiation of von Willebrand disease type 2B from platelet-type vWD. FASEB journal, 27(871), 3.